Pyoderma gangrenosum (PG) is a rare, ulcerative skin condition of unknown origin, with an annual incidence of 3 to 10 cases per million people. Skin lesions develop as painful, edematous nodules or ...

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

A 2-point improvement in pain based on a numeric rating scale may indicate that patients are responding to treatment for pyoderma gangrenosum. To help determine whether a patient with pyoderma ...

US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosum Fast track follows recently reported orphan drug designation by both US FDA and EMA ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...

Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design Type B meeting scheduled with FDA; dialogue ongoing with EMA for development in severe ...

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...

InflaRx N.V. has announced the presentation of data on vilobelimab, its anti-inflammatory therapeutic targeting the complement system, at the 2025 American Academy of Dermatology Annual Meeting. The ...

A systematic review of 63 cases found that pyoderma gangrenosum (PG) during pregnancy or postpartum was often misdiagnosed, delaying treatment and leading to inappropriate interventions. Researchers ...